Regenxbio Faces Class Action for Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy RGNX?
Source: Globenewswire
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses when the truth emerged, indicating that the company's public statements were false and materially misleading throughout the class period.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant treated in the RGX-111 study further confirms the company's concealment of product safety, potentially eroding investor confidence and affecting future financing capabilities for the company.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to participate in the lawsuit to seek compensation, highlighting the legal avenue available for investors to recover their losses.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGNX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGNX
Wall Street analysts forecast RGNX stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.490
Low
19.00
Averages
29.71
High
45.00
Current: 9.490
Low
19.00
Averages
29.71
High
45.00
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Regenxbio Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses when the truth emerged, indicating that the company's public statements were false and materially misleading throughout the class period.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant treated in the RGX-111 study further confirms the company's concealment of product safety, potentially eroding investor confidence and affecting future financing capabilities for the company.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to participate in the lawsuit to seek compensation, highlighting the legal avenue available for investors to recover their losses.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Choosing Legal Counsel: The firm emphasizes the importance of selecting qualified legal representation with a proven track record, noting that many firms issuing notices may lack the necessary experience and resources to effectively handle securities class actions.
- Case Background: The lawsuit alleges that defendants provided misleading information regarding REGENXBIO's RGX-111 gene therapy development, concealing adverse facts about its efficacy and safety, which resulted in investor losses when the truth emerged.
- Historical Achievements: In 2019, Rosen Law Firm secured over $438 million for investors and was ranked first by ISS Securities Class Action Services in 2017 for the number of settlements, showcasing its strong capabilities and influence in the securities litigation field.
See More
Notice of Class Action Lawsuit Against REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that REGENXBIO misled investors regarding its RGX-111 gene therapy development, providing false and misleading information while claiming positive biomarker and safety data from ongoing Phase I/II studies.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong reputation in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record in securities class actions to ensure effective legal representation, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO, alleging violations of federal securities laws from February 9, 2022, to January 27, 2026, seeking damages for investors, highlighting significant investor concerns regarding corporate transparency.
- False Statement Allegations: The complaint claims that REGENXBIO made materially misleading statements regarding the development of RGX-111 gene therapy, particularly that positive expectations about its clinical trial lacked a reasonable basis, potentially leading investors to misjudge the company's prospects.
- Investor Rights Protection: Affected investors have until April 14, 2026, to request to be appointed as lead plaintiff, indicating the potential impact of this case on investors and their opportunity to participate in the legal process, emphasizing the importance of legal recourse.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, showcasing its expertise in securities fraud class actions, which enhances investor confidence in the potential outcomes of the case.
See More
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, potentially impacting numerous investors who traded between February 9, 2022, and January 27, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made overly optimistic statements regarding its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses once the truth emerged.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant during the RGX-111 study has rendered the company's prior public statements false and misleading, exacerbating investor damages as the market reacted to this critical information.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected investors to contact them before April 14, 2026, to participate in the lawsuit and seek compensation, highlighting the firm's commitment to protecting investor rights and the necessity of legal support.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Case Background: The lawsuit alleges that defendants misled investors regarding the development of REGENXBIO's RGX-111 gene therapy, providing overly positive statements while concealing material adverse facts about the trial's efficacy and safety, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone and achieving the largest securities class action settlement against a Chinese company in 2017, highlighting its strong track record in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
Regenxbio Faces Class Action for Securities Fraud
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 9, 2022, and January 27, 2026, with a deadline to contact the firm by April 14, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made overly positive statements about its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses when the truth emerged, indicating that the company's public statements were false and materially misleading throughout the class period.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant treated in the RGX-111 study further confirms the company's concealment of product safety, potentially eroding investor confidence and affecting future financing capabilities for the company.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to participate in the lawsuit to seek compensation, highlighting the legal avenue available for investors to recover their losses.
See More
Notice of REGENXBIO Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Choosing Legal Counsel: The firm emphasizes the importance of selecting qualified legal representation with a proven track record, noting that many firms issuing notices may lack the necessary experience and resources to effectively handle securities class actions.
- Case Background: The lawsuit alleges that defendants provided misleading information regarding REGENXBIO's RGX-111 gene therapy development, concealing adverse facts about its efficacy and safety, which resulted in investor losses when the truth emerged.
- Historical Achievements: In 2019, Rosen Law Firm secured over $438 million for investors and was ranked first by ISS Securities Class Action Services in 2017 for the number of settlements, showcasing its strong capabilities and influence in the securities litigation field.
See More
Notice of Class Action Lawsuit Against REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that REGENXBIO misled investors regarding its RGX-111 gene therapy development, providing false and misleading information while claiming positive biomarker and safety data from ongoing Phase I/II studies.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, having achieved the largest securities class action settlement against a Chinese company in 2017, showcasing its strong reputation in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record in securities class actions to ensure effective legal representation, avoiding firms that merely act as intermediaries without substantial litigation experience.
See More
REGENXBIO Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against REGENXBIO, alleging violations of federal securities laws from February 9, 2022, to January 27, 2026, seeking damages for investors, highlighting significant investor concerns regarding corporate transparency.
- False Statement Allegations: The complaint claims that REGENXBIO made materially misleading statements regarding the development of RGX-111 gene therapy, particularly that positive expectations about its clinical trial lacked a reasonable basis, potentially leading investors to misjudge the company's prospects.
- Investor Rights Protection: Affected investors have until April 14, 2026, to request to be appointed as lead plaintiff, indicating the potential impact of this case on investors and their opportunity to participate in the legal process, emphasizing the importance of legal recourse.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is recognized for recovering hundreds of millions for investors, showcasing its expertise in securities fraud class actions, which enhances investor confidence in the potential outcomes of the case.
See More
Regenxbio Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regenxbio for violations of §§10(b) and 20(a) of the Securities Exchange Act, potentially impacting numerous investors who traded between February 9, 2022, and January 27, 2026.
- False Statements Exposed: The complaint alleges that Regenxbio made overly optimistic statements regarding its product candidate RGX-111 while concealing negative efficacy and safety data, leading to significant investor losses once the truth emerged.
- Tumor Discovery Impact: The revelation of an intraventricular CNS tumor in a participant during the RGX-111 study has rendered the company's prior public statements false and misleading, exacerbating investor damages as the market reacted to this critical information.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected investors to contact them before April 14, 2026, to participate in the lawsuit and seek compensation, highlighting the firm's commitment to protecting investor rights and the necessity of legal support.
See More
Notice of Class Action Lawsuit for REGENXBIO Securities
- Class Action Notice: Rosen Law Firm reminds investors who purchased REGENXBIO (NASDAQ: RGNX) securities between February 9, 2022, and January 27, 2026, to apply as lead plaintiffs by April 14, 2026, to potentially receive compensation without any out-of-pocket costs.
- Case Background: The lawsuit alleges that defendants misled investors regarding the development of REGENXBIO's RGX-111 gene therapy, providing overly positive statements while concealing material adverse facts about the trial's efficacy and safety, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone and achieving the largest securities class action settlement against a Chinese company in 2017, highlighting its strong track record in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with proven success in securities litigation, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action.
See More
